CEO Total Pay
$1.6M
FY2024 Summary Compensation, below median
MRSN FY2024 SEC EDGAR DEF 14A
Mersana Therapeutics, Inc. CEO pay ratio
The CEO earned $1.6M in FY2024 against median worker pay of $316,460 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2025-04-29
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2024
Data updated August 2026
Subscribe to Mersana Therapeutics, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
5:1
Below Average (Scale: 0–1000:1)
CEO pay
$1.6M
Median worker
$316,460
Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Mersana Therapeutics, Inc. reported a 5:1 CEO-to-worker pay ratio in FY2024 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 5:1
- FY2024 disclosed
- CEO total
- $1.6M
- Summary Compensation Table total
- Median worker
- $316,460
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2024
A component-level pay breakdown is not reported in Mersana Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Mersana Therapeutics, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2024. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 5:1
- FY2024
- vs prior FY
- +4:1
- from FY2023 1:1
- CEO $ YoY
- +401%
- $1.6M latest
- Filings shown
- 3
- FY2021–2024
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $8.2M | - | $302,642 | 27:1 | - |
| 2023 | $316K | -96% | $315,949 | 1:1 | -26:1 |
| 2024 | $1.6M | +401% | $316,460 | 5:1 | +4:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1442836, FY2021–2024. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
5:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$1.6M
Companies in Industry
168
vs. Industry Median
Below
Mersana Therapeutics, Inc.: near-parity Item 402(u) ratio
Mersana Therapeutics, Inc. stamps FLOOR · ELITE-MED at 5:1 against $316,460 median worker pay in FY2024. the CEO earned 5× the median employee ($316,460) in FY2024.
At $316,460 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.
Pay Ratio
5:1
Below typical
What FY2024 shows for Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. stamps FLOOR · ELITE-MED at 5:1 against $316,460 median worker pay in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Mersana Therapeutics, Inc.'s $1.6M CEO total is at or below the $7.9M industry median CEO pay.
Mersana Therapeutics, Inc. stamps FLOOR · LIGHT · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2024
- Total Compensation
- $1.6M
- Median Employee Pay
- $316,460
- Pay Ratio
- 5:1
- Filing Date
- 2025-04-29
Company Info
- Ticker
- MRSN
- CIK
- 1442836
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1442836, FY2024. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Mersana Therapeutics, Inc. stamps FLOOR · ELITE-MED at 5:1 against $316,460 median worker pay in FY2024.
Read with Mersana Therapeutics, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.
Great Southern Bancorp, Inc. · LIGHT
ABS(ceo_total_comp) peer at $1.6M (Δ $1K heavier vs Mersana Therapeutics, Inc.); MODEST · LOW-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Clearfield, Inc. · LIGHT
ABS(ceo_total_comp) peer at $1.6M (Δ $3K heavier vs Mersana Therapeutics, Inc.); MODEST · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
FS Bancorp, Inc. · LIGHT
ABS(ceo_total_comp) peer at $1.6M (Δ $19K lighter vs Mersana Therapeutics, Inc.); MODEST · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Qcr Holdings Inc · LIGHT
ABS(ceo_total_comp) peer at $1.6M (Δ $24K lighter vs Mersana Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Mersana Therapeutics, Inc. stamps FLOOR · LIGHT · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · LIGHT packages sit on the national leaderboard after reading Mersana Therapeutics, Inc..
Ratio primer · FLOOR
Mersana Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Mersana Therapeutics, Inc. (CIK 1442836), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.